Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2022 Earnings Conference Call February 16, 2023 8:00 AM ET
Company Participants
Jenna Cohen - Senior Director and Head of Investor Relations
Kate Haviland - Chief Executive Officer
Philina Lee - Chief Commercial Officer
Christy Rossi - Chief Operating Officer
Mike Landsittel - Chief Financial Officer
Fouad Namouni - President of Research and Development
Becker Hewes - MD, Chief Medical Officer
Conference Call Participants
Dane Leone - Raymond James
Ernie Rodriguez - Cowen and Co
Brad Canino - Stifel
Eun Yang - Jefferies
Derek Archila - Wells Fargo
Michael Ulz - Morgan Stanley
Reni Benjamin - JMP Securities
Joe Beatty - Baird
Peter Lawson - Barclays
David Lebowitz - Citi
Zhi Shu - Berenberg
Ami Fadia - Needham
Matt Biegler - Oppenheimer
Nicole Gabreski - Piper Sandler
Operator
Good morning, and welcome to the Blueprint Medicines Conference Call. At this time, all participants are in listen-only-mode. Following the formal remarks, we will open the call up for your questions. Please be advised that this call is being recorded.
At this time, I'd like to turn over to Jenna Cohen, Head of Investor Relations at Blueprint Medicines. Please proceed.
Jenna Cohen
Thank you, operator. Good morning, everyone. Welcome to Blueprint Medicines fourth quarter and full year 2022 financial and operating results conference call. This morning, we issued a press release, which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.
Today on our call, Kate Haviland, our Chief Executive Officer, will provide a perspective on Blueprint's 2022 accomplishments and how that positions us to continue to grow and drive value in 2023. Philina Lee, our Chief Commercial Officer, will review AYVAKIT's performance and our upcoming opportunity to expand the label and treat many more patients with SM. Christy Rossi, Chief Operating Officer, will provide a preview of how we will further our SM leadership at Quad AI [ph] as well as touch on portfolio milestones for the year; and Mike Landsittel, our Chief Financial Officer, will review our fourth quarter 2022 financial results and 2023 guidance. Fouad Namouni, President of Research and Development; and Becker Hewes, Chief Medical Officer, are also joining our call and will be available for Q&A.
Before we get started, I would like to remind everyone that the statements me make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in the Risk Factors section of SEC filings. In addition, any forward-looking statement made on this call represents our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements.